Warning letter follows ban for Chinese API maker Jinan Jinda Pharmaceutical

FDA
The FDA has issued a warning letter to Jinan Jinda Pharmaceutical Chemistry, a Chinese API maker whose products have been banned since 2015.

After being put on an import alert by the FDA and running into problems with European regulators, Chinese API maker Jinan Jinda Pharmaceutical Chemistry announced it had hired a consultant to get its plant in order. But in a recent warning letter, the FDA said its efforts are still not enough.

The letter, issued last month, was based on an inspection in June at the plant in Zhangqiu City, Shandong Province, which found lots of problems with scant inspection on out-of-spec test results and plenty of examples of deleted test results.

The letter says that plant’s quality control laboratory disregarded multiple out-of-spec impurity results without justification and then manually reset testing equipment to exclude a peak result. Despite hiring a consultant, the FDA said that the company did not have an adequate interim plan while working to resolve its testing issues.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The FDA found other data integrity concerns, including multiple instances in which data was deleted and said that the company didn’t have adequate safeguards on its computers to prevent the problem.   

The warning letter follows a recommendation in June from the European Directorate for the Quality of Medicines that Jinan Jinda's nitrofurantoin antibiotic be banned from the EU and that the plant's certificate of compliance be suspended or even “voided.” That came after Italian inspectors reported a follow-up visit in which they found raw supplies and finished products in a room in which the door had been screwed shut by employees. Inspectors "concluded there was a serious risk of data falsification" related to the ingredients in the room.

Suggested Articles

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.

After a global scare over Zantac contamination, generic metformin could be next in line as regulators test for possible carcinogen contamination.

PCI Pharma Services debuts expansion of its plant in Rockford, Illinois.